Liquidia Corp(LQDA) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Liquidia Corporation Reports Third Quarter 2024 Financial Results and Provides Corporate Update · Received tentative approval from the FDA for YUTREPIA™ (treprostinil) inhalation powder for both pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) · U.S. Supreme Court rejected final appeal of '793 patent decision, marking victories with respect to three patents originally asserted final and not subject to further appeal · Strengthen ...